Catharanthine alkaloids are noncompetitive antagonists of muscle-type nicotinic acetylcholine receptors

Neurochemistry International

Volumn 57, Issue 2, 2010, Pages 153-161

  Arias, Hugo R ^a   Feuerbach, Dominik ^b   Targowska Duda, Katarzyna M ^c   Jozwiak, Krzysztof ^c  

^a MIDWESTERN UNIVERSITY   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Ca2+ influx; Catharanthine alkaloids; Ibogaine; Molecular modeling; Nicotinic acetylcholine receptors; Noncompetitive antagonists; Nonformational states; Vinca alkaloids

Indexed keywords

CATHARANTHINE; IBOGAINE; NICOTINIC RECEPTOR; PHENCYCLIDINE; VINBLASTINE; VINCRISTINE; CALCIUM; ION CHANNEL; NICOTINIC RECEPTOR BLOCKING AGENT; TRITIUM; VINCA ALKALOID;

ARTICLE; BINDING AFFINITY; CALCIUM TRANSPORT; CONTROLLED STUDY; DESENSITIZATION; DRUG POTENCY; DRUG RECEPTOR BINDING; ELECTRICITY; HYDROGEN BOND; IC 50; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN INTERACTION; ANIMAL; CELL LINE; DRUG EFFECTS; HUMAN; ION TRANSPORT; METABOLISM; MUSCLE; RADIOASSAY; TORPEDO;

ANIMALS; CALCIUM; CELL LINE; HUMANS; IBOGAINE; ION CHANNELS; ION TRANSPORT; MUSCLES; NICOTINIC ANTAGONISTS; RADIOLIGAND ASSAY; RECEPTORS, NICOTINIC; TORPEDO; TRITIUM; VINCA ALKALOIDS;

VINCA;

EID: 77953911700     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2010.05.007     Document Type: Article

References (34)

1. Albuquerque E.X., et al. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol. Rev. 2009, 89:73-120.
2. Arias H.R. Ligand-gated ion channel receptor superfamilies. Biological and Biophysical Aspects of Ligand-Gated Ion Channel Receptor Superfamilies 2006, 1-25. Research Signpost, Kerala, India, Chapter 1. H.R. Arias (Ed.).
3. Arias H.R. Is the inhibition of nicotinic acetylcholine receptors by bupropion involved in its clinical actions?. Int. J. Biochem. Cell Biol. 2009, 41:2098-2108.
4. Arias H.R., et al. Noncompetitive antagonist binding sites in the Torpedo nicotinic acetylcholine receptor ion channel. Structure-activity relationship studies using adamantane derivatives. Biochemistry 2003, 42:7358-7370.
5. Arias H.R., et al. Molecular mechanisms and binding site locations for noncompetitive antagonists of nicotinic acetylcholine receptors. Int. J. Biochem. Cell Biol. 2006, 38:1254-1276.
6. Arias H.R., et al. Molecular mechanisms and binding site location for the noncompetitive antagonist crystal violet on nicotinic acetylcholine receptors. Biochemistry 2006, 45:2014-2026.
7. Arias H.R., et al. Interaction of bupropion with muscle-type nicotinic acetylcholine receptors in different conformational states. Biochemistry 2009, 48:4506-4518.
8. Arias H.R., et al. Interaction of 18-methoxycoronaridine with muscle nicotinic receptors in different conformational states. Biochem. Biophys. Acta - Biomembranes 2010, 1798:1153-1163.
9. Arias H.R., et al. Inhibitory mechanisms and binding site locations for serotonin selective reuptake inhibitors on nicotinic acetylcholine receptors. Int. J. Biochem. Cell Biol. 2010, 42:712-724.
10. Arias H.R., et al. Different interaction between tricyclic antidepressants and mecamylamine with the human α3β4 nicotinic acetylcholine receptor. Int. Neurochem. 2010, 56:642-649.
11. Arias H.R., et al. Tricyclic antidepressants and mecamylamine bind to different sites in the human α4β2 nicotinic receptor ion channel. Int. J. Biochem. Cell Biol. 2010, 42:1007-1018.
12. Badio B., et al. Ibogaine: a potent noncompetitive blocker of ganglionic/neuronal nicotinic receptors. Mol. Pharmacol. 1997, 51:1-5.
13. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22:3099-3108.
14. Eaton M.J., et al. M2 Mutations of the nicotinic acetylcholine receptor increase the potency of the non-competitive inhibitor phencyclidine. J. Neurosci. Res. 2000, 61:44-51.
15. Fryer J.D., Lukas R.J. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J. Pharmacol. Exp. Ther. 1999, 288:88-92.
16. Gerzanich V., et al. Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors. Mol. Pharmacol. 1995, 48:774-782.
17. Glick S.D., Maisonneuve I.M. Mechanisms of antiaddictive actions of ibogaine. Ann. N. Y. Acad. Sci. 1998, 844:214-226.
18. Glick S.D., et al. Antagonism of α3β4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration. Eur. J. Pharmacol. 2002, 438:99-105.
19. Glick S.D., et al. 18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action. Ann. N. Y. Acad. Sci. 2000, 914:369-386.
20. Gotti C., Zoli M., Clementi F. Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharm. Sci. 2006, 27:482-491.
21. Hamouda A.K., et al. Probing the structure of the affinity-purified and lipid-reconstituted Torpedo nicotinic acetylcholine receptor. Biochemistry 2008, 47:12787-12794.
22. Houghton J.A., et al. Determinants of intrinsic sensitivity to vinca alkaloids in xenografts of pediatric rhabdomyosarcomas. Cancer Res. 1984, 44:582-590.
23. McKay D.B., et al. Interactions of microtubule-active agents with nicotinic acetylcholine receptors. Relationship to their inhibition of catecholamine secretion by adrenal chromaffin cells. Mol. Pharmacol. 1985, 28:10-16.
24. Michelmore S., et al. Study of the calcium dynamics of the human α4β2alpha;3β4 and α1β1γδ nicotinic acetylcholine receptors. Naunyn-Schmiedebergs Arch. Pharmacol. 2002, 366:235-245.
25. Miyazawa A., et al. Structure and gating mechanism of the acetylcholine receptor pore. Nature 2003, 423:949-955.
26. Moore M.A., McCarthy M.P. Snake venom toxins, unlike smaller antagonists, appear to stabilize a resting state conformation of the nicotinic acetylcholine receptor. Biochem. Biophys. Acta 1995, 1235:336-342.
27. Ortells M.O., Barrantes G.E. Tobacco addiction: a biochemical model of nicotine dependence. Med. Hypotheses 2010, 74:884-894.
28. Pace C.J., et al. Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration. Eur. J. Pharmacol. 2004, 492:159-167.
29. Pagán O.R., et al. Cembranoid and long-chain alkanol sites on the nicotinic acetylcholine receptor and their allosteric interaction. Biochemistry 2001, 40:11121-11130.
30. Pedersen S.E., et al. Location of ligand-binding sites on the nicotinic acetylcholine receptor alpha-subunit. J. Biol. Chem. 1986, 261:13735-13743.
31. Roche V.F. Cancer and chemotherapy. Foye's Principles of Medicinal Chemistry 2008, 1147-1192. Lippincott Williams and Wilkins, USA. 6th edition. T.L. Lemke, D.A. Williams (Eds.).
32. Sanghvi M., et al. Identifying the binding site(s) for antidepressants on the Torpedo nicotinic acetylcholine receptor: [3H]2-Azidoimipramine photolabeling and molecular dynamics studies. Biochem. Biophys. Acta 2008, 1778:2690-2699.
33. Schild H.O. pAx and competitive drug antagonism. Br. J. Pharmacol. 1949, 4:277-280.
34. Unwin N. Refined structure of the nicotinic acetylcholine receptor at 4Å resolution. J. Mol. Biol. 2005, 346:967-989.